Drugs / DHEA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02683148 | Sep 2016 → Sep 2018 | synovial sarcoma | Washington University School of Medicine | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHEA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02683148 ↗ |
| Action | Inhibit | “DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD).” NCT02683148 ↗ |
| Route | Oral | “DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.” NCT02683148 ↗ |
| Target | G6PD | “DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD).” NCT02683148 ↗ |